国药集团一致药业股份有限公司 关于国药集团财务有限公司的风险持续评估报告 通过查验国药集团财务有限公司（以下简称国药财务公司）《金 融许可证》《营业执照》等证件资料，并审阅了国药财务公司截至2024 年12月31日的财务报告以及风险指标等必要信息，对国药财务公司的 经营资质、业务和风险状况进行了评估，具体情况报告如下： 一、国药财务公司基本情况 国药财务公司成立于2012年2月，是经原中国银行业监督管理委 员会批准成立的非银行金融机构。 企业名称：国药集团财务有限公司 注册地址：北京市海淀区知春路20号 法定代表人：杨珊华 金融许可证机构编码：L0145H211000001 统一社会信用代码：9111000071783212X7 目前国药财务公司注册资本金为人民币220,000万元，股权结构 如下表所示： | 序号 | 股东名称 | 出资额（万元） | 持股比例 | | --- | --- | --- | --- | | 1 | 中国医药集团有限公司 | 116,105 | 52.7750% | | 2 | 中国生物技术股份有限公司 | 69,895 | 31.7705% | | 3 | 中国中药有限公司 | ...

国药集团一致药业股份有限公司 关于公司与国药融汇（上海）商业保理有限公司 开展应收账款保理业务暨关联交易的公告 本公司及董事全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-20 1.公司拟与国药融汇（上海）商业保理有限公司（简称"国药融 汇"）签订应收账款保理业务合同； 2.本次交易构成关联交易，尚须提交公司股东大会表决。 一、 关联交易概述 为控制应收风险、优化运营周期，国药一致及下属子公司拟与 国药融汇（上海）商业保理有限公司（简称"国药融汇"）开展应收账 款保理业务，信用额度不超过 8 亿元，期限 1 年。2025 年预计支付 国药融汇利息费用 4,000 万元。 2025 年 4 月 3 日，公司召开第十届董事会第四次会议对《关于 公司与国药融汇（上海）商业保理有限公司开展应收账款保理业务暨 关联交易的议案》进行了审议，关联董事吴壹建、罗娴、李进雄已回 避表决，非关联董事以 4 票同意、0 票反对、0 票弃权的表决结果审 议通过了上述议案，该议案尚须提交公司股东大会审 ...

证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2025-24 1．股东大会届次：2024年年度股东大会 国药集团一致药业股份有限公司 关于召开公司 2024 年年度股东大会的通知 本公司及董事全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、召开会议基本情况 2．股东大会的召集人：公司董事会 公司第十届董事会第四次会议审议通过了《关于召开公司2024 年年度股东大会的议案》，同意召开本次年度股东大会。 3．会议召开的合法、合规性：本次股东大会的召集、召开符合 有关法律、行政法规、部门规章、规范性文件、深交所业务规则和《公 司章程》的相关规定。 4．会议召开的日期、时间： （1）现场会议时间：2025年6月10日（星期二）上午9:30。 （2）网络投票时间： 通过深圳证券交易所交易系统进行投票的时间为2025年6月10日 9:15-9:25，9:30-11:30和13:00-15:00； 通过深圳证券交易所互联网投票系统投票时间为2025年6月10日 9:15-15:00期间的任意时间。 5．会议召开方式：本次股东大会采取现场投票及网络投票相结 ...

证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2025-15 国药集团一致药业股份有限公司 第十届监事会第四次会议决议公告 本公司及监事全体人员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 公司第十届监事会第四次会议于2025年3月24日以电话和电子邮 件方式发出通知和文件材料，会议于2025年4月3日在上海以现场结合 视频会议方式召开，监事会主席文德镛先生主持会议。会议应参会监 事3人，实际参会监事3人。会议召开程序符合《公司法》《公司章程》 的有关规定。监事列席了第十届董事会第四次会议。 一、以3票同意、0票反对、0票弃权审议通过《公司2024年度监 事会工作报告》； 《公司2024年度监事会工作报告》已于同日披露于巨潮资讯网。 本议案需提交股东大会审议。 二、以3票同意、0票反对、0票弃权审议通过《公司2024年年度 报告及摘要》； 经审核，监事会认为董事会编制和审议《公司2024年年度报告及 摘要》的程序符合法律、行政法规及中国证监会的规定，报告内容真 实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 ...

证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-14 国药集团一致药业股份有限公司 第十届董事会第四次会议决议公告 本公司及董事全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 公司第十届董事会第四次会议于2025年3月24日以电话和电子邮 件方式发出通知和文件材料，会议于2025年4月3日在上海以现场结合 视频会议方式召开，董事长吴壹建先生主持会议。应参加会议董事7 名，亲自出席会议董事7名。公司监事、高管列席了会议。会议召开 程序符合《公司法》《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议表决，本次会议审议和听取了下列事项并形成相 关决议。 1. 审议通过了《公司 2024 年度董事会工作报告》 表决结果：7 票同意，0 票反对，0 票弃权。本议案须提交公司 2024 年年度股东大会审议。（具体内容详见当日公告及巨潮资讯网） 2. 听取了《公司 2024 年度独立董事述职报告》（具体内容详 见巨潮资讯网） 3. 审议通过了《公司 2024 年度总经理工作报告》 经天健会计师事务所（特殊普通合 ...

证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-17 国药集团一致药业股份有限公司 关于2024年度利润分配方案的公告 本公司及董事全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、审议程序 2025 年 4 月 3 日，国药集团一致药业股份有限公司（以下简称"公司"） 第十届董事会第四次会议审议通过了《公司 2024 年度利润分配方案》，表 决结果：同意 7 票，反对 0 票，弃权 0 票。本议案尚需提交公司 2024 年 年度股东大会审议。 二、利润分配预案的基本情况 经天健会计师事务所（特殊普通合伙）审计确认，公司 2024 年度合并 会计报表归属于母公司股东的净利润为人民币 642,493,449.76 元，2024 年 末合并报表未分配利润为人民币 12,575,550,286.60 元，母公司会计报表净 利润为人民币 1,016,628,471.49 元。 根据《公司法》和本《公司章程》的有关规定，利润分配以母公司会 计报表净利润人民币 1,016,628,471.49 元为基准，加上年初未分配利润人民 币 7,504, ...

Financial Performance - The company's basic earnings per share decreased to 1.15 yuan, a decline of 59.93% compared to 2.87 yuan in the previous year [1] - Net profit fell to 6.42 billion yuan, down 59.85% from 15.99 billion yuan in the previous year [1] - Operating revenue slightly decreased to 74.378 billion yuan, a reduction of 1.46% from 75.477 billion yuan in the previous year [1] - Return on equity dropped to 3.67%, down 61.61% from 9.56% in the previous year [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 35,592.8 million shares, accounting for 64.79% of the circulating shares, with a decrease of 599.67 million shares compared to the previous period [2] - The largest shareholder, China National Pharmaceutical Group Corporation, holds 30,484.25 million shares, maintaining its position [3] - New entrants among the top shareholders include several investment funds, indicating a shift in the shareholder composition [3] Dividend Distribution - The company announced a dividend distribution of 3.66 yuan per share (including tax) [4]

Financial Performance - The company reported a revenue of CNY 74.38 billion for 2024, a decrease of 1.46% compared to CNY 75.48 billion in 2023[15]. - Net profit attributable to shareholders was CNY 642.49 million, down 59.83% from CNY 1.60 billion in the previous year[15]. - The basic earnings per share decreased to CNY 1.15, a decline of 59.93% from CNY 2.87 in 2023[15]. - The company’s total assets at the end of 2024 were CNY 47.56 billion, a slight decrease of 0.03% from CNY 47.57 billion in 2023[15]. - Operating cash flow increased by 11.38% to CNY 3.27 billion, compared to CNY 2.94 billion in 2023[15]. - The weighted average return on equity decreased by 5.89 percentage points to 3.67% from 9.56% in the previous year[15]. - The company's total revenue for Q1 2024 was approximately ¥19.09 billion, showing a decline to ¥17.91 billion in Q4 2024, representing a decrease of about 6.2% quarter-over-quarter[19]. - The net profit attributable to shareholders for Q1 2024 was approximately ¥388.77 million, which fell to a loss of ¥423.05 million in Q4 2024, indicating a significant decline in profitability[19]. - The cash flow from operating activities showed a positive net amount of approximately ¥1.99 billion in Q4 2024, recovering from a negative cash flow of approximately ¥634.15 million in Q1 2024[19]. - The company achieved operating revenue of 74.378 billion yuan in 2024, a year-on-year decrease of 1.46%[44]. - The net profit attributable to shareholders was 642 million yuan, down 59.83% year-on-year[44]. - The distribution segment generated operating revenue of 52.984 billion yuan, an increase of 1.98% year-on-year, while the retail segment (Guoda Pharmacy) reported revenue of 22.357 billion yuan, a decline of 8.41%[45]. - The company recorded a net cash flow from operating activities of 3.271 billion yuan, an increase of 11.38% year-on-year[46]. - The asset-liability ratio at the end of the reporting period was 56.36%, an increase of 0.46 percentage points year-on-year[51]. - The company reported a weighted average return on net assets of 3.67%, a decrease of 5.89 percentage points year-on-year[44]. - The company’s cash ratio improved to 0.29, indicating enhanced short-term solvency and risk management capabilities[51]. Market Challenges - The decline in profit was attributed to increased market competition and changes in industry policies affecting the retail sector[15]. - The company is facing challenges from the ongoing medical insurance payment reforms and centralized procurement policies, which are compressing profit margins and increasing competition[26]. - The pharmaceutical distribution industry is projected to see a 1.2% year-over-year decline in drug sales, with an estimated total sales of ¥186.38 billion in 2024[25]. - The implementation of DRG/DIP payment reform is prompting the company to adjust its operational strategies, emphasizing cost control and optimizing product structure[29]. - The government has introduced stricter regulations on medical insurance fund management, requiring the company to enhance compliance and internal management practices[31]. - The company anticipates challenges in profitability due to increased market competition and regulatory impacts on operational efficiency in both distribution and retail sectors[106]. Strategic Initiatives - The company is focusing on enhancing its supply chain and retail capabilities, aiming to establish a leading smart supply chain value system and a professional retail brand for prescription drugs[32]. - The company is investing in digitalization and smart technologies to improve operational efficiency and meet the evolving demands of the pharmaceutical distribution market[25]. - The company aims to enhance overall competitiveness through the collaborative development of three major business segments, focusing on high-margin and high-growth products[109]. - The retail segment plans to achieve digital transformation and diversify its operations, with a focus on improving operational quality and closing unprofitable stores[109]. - The company is committed to leveraging technology to optimize supply chain management and reduce costs, providing customized solutions to maintain competitive advantages[102]. Governance and Compliance - The company has established a comprehensive internal control system covering governance, management control, financial control, and operational management, ensuring compliance with relevant laws and regulations[158]. - The company has improved its governance structure by revising internal control systems and enhancing management quality[115]. - The company maintains complete independence from its controlling shareholders in business, personnel, and financial aspects[116]. - The company has a clear separation of assets from its controlling shareholders, ensuring independent operations[117]. - The company has established independent financial departments and tax compliance systems[117]. - The company has committed to improving investor relations and information disclosure practices[115]. - The company is committed to maintaining compliance and governance standards through its newly appointed legal and compliance officers[123]. Employee and Talent Management - The total number of employees at the end of the reporting period is 34,831, with 127 from the parent company and 34,704 from major subsidiaries[147]. - The professional composition includes 26,670 sales personnel, 15 production personnel, 409 technical personnel, 709 financial personnel, and 197 administrative personnel[147]. - The company emphasizes a dual approach of "internal cultivation and external recruitment" to enhance talent development and ensure a sustainable talent supply chain[150]. - The company has implemented a "Potential Dragon Plan" for talent development, focusing on a comprehensive training chain to cultivate backup talent[151]. - The company has established a multi-level and multi-type employee training system to promote comprehensive skill enhancement among employees[152]. Environmental Management - The company has established a comprehensive environmental monitoring system, enhancing the management efficiency of pollution control facilities[165]. - The company has implemented a complete environmental management system to ensure compliance with environmental laws and regulations for construction projects[166]. - Emergency response plans for environmental pollution incidents have been developed and regularly practiced to improve the company's emergency handling capabilities[167]. - The company reported no administrative penalties for environmental issues during the reporting period[164]. - The company has taken measures to reduce carbon emissions, as detailed in the 2024 ESG report[169]. Related Party Transactions - The company reported that related party purchases accounted for 83.62% of the total expected amount for the year, while related party sales accounted for 68.72%[187]. - Related party services provided accounted for 86.03% of the total expected amount, and services received accounted for 77.01%[187]. - The total amount of related party transactions across various categories accounted for 81.55% of the total expected amount for the year[187]. - The company has a maximum daily deposit limit of CNY 30,000,000 with its related party financial company, with a deposit interest rate of 0.35%[191]. - The company had a loan limit of CNY 120,000,000 with its related party financial company, with an interest rate range of 2.35% to 2.90%[191]. Management Changes - The company experienced significant management changes, with multiple directors and executives resigning or being appointed throughout 2024[123]. - The company is expanding its leadership team with new appointments, including several Vice General Managers and independent directors[123]. - The company has a focus on enhancing its governance structure with the election of new independent directors in July 2024[123]. - The current chairman, Wu Yijian, has been in position since November 13, 2020[121]. - Lin Min resigned as Chairman on January 18, 2024, and as a Director on February 18, 2024, due to work arrangement adjustments[123].

[ T able_StockInfo] 2025 年 03 月 20 日 证券研究报告•2024 年业绩快报点评 国药一致（000028）医药生物 目标价：33.18 元（6 个月） 买入 （维持） 当前价：26.27 元 商誉减值致短期承压，2025 年经营有望改善 | 指标/年度 | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 75477.48 | 74378.49 | 78097.42 | 83564.24 | | 增长率 | 2.77% | -1.46% | 5.00% | 7.00% | | 归属母公司净利润（百万元） | 1599.26 | 642.49 | 1318.46 | 1492.62 | | 增长率 | 7.57% | -59.83% | 105.21% | 13.21% | | 每股收益 EPS（元） | 2.87 | 1.15 | 2.37 | 2.68 | | 净资产收益率 ROE | 9.34% | 3.91% | 7.03% | 7.48% | | PE | 9 | ...

证券代码：000028 、200028 证券简称：国药一致、一致B 公告编号：2025-12 国药集团一致药业股份有限公司（以下简称"公司"）于 2025 年 3 月 14 日召开第十届董事会 2025 年第四次临时会议，审议通过了 《关于拟计提资产减值准备的议案》,根据《深圳证券交易所股票上市 规则》等相关规定，现将公司计提资产减值准备的具体情况公告如下： 关于计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《企业会计准则》、《深圳证券交易所股票上市规则》以及 公司会计政策等相关规定，为了更加客观真实反映公司截至 2024 年 12 月 31 日的财务状况和资产价值，基于谨慎性原则，公司 2024 年 度相关资产拟计提的资产减值准备情况如下： 一、本次拟计提资产减值准备情况概述 国药集团一致药业股份有限公司 根据《企业会计准则》及公司会计政策相关规定，基于谨慎性原 则，公司对合并报表范围内各类资产进行了检查和分析，对可能发 生资产减值损失的相关资产拟计提减值准备。具体情况如下表所 示： 单位：人民币万元 | 类别 | 项目 | 拟 ...